Literature DB >> 31302151

BAY 41-4109-mediated aggregation of assembled and misassembled HBV capsids in cells revealed by electron microscopy.

Virgile Rat1, Florian Seigneuret1, Julien Burlaud-Gaillard2, Roxane Lemoine3, Christophe Hourioux4, Fabien Zoulim5, Barbara Testoni5, Jean-Christophe Meunier1, Clovis Tauber6, Philippe Roingeard4, Hugues de Rocquigny7.   

Abstract

HBc is a small protein essential for the formation of the icosahedral HBV capsid. Its multiple roles in the replication cycle make this protein a promising target for the development of antiviral molecules. Based on the structure of HBc, a series of HBV assembly inhibitors, also known as capsid assembly modulators, were identified. We investigated the effect of BAY 41-4109, a heteroaryldihydropyrimidine derivative that promotes the assembly of a non-capsid polymer. We showed, by confocal microscopy, that BAY 41-4109 mediated HBc aggregation, mostly in the cytoplasm of Huh7 cells. Image analysis revealed that aggregate size depended on BAY 41-4109 concentration and treatment duration. Large aggregates in the vicinity of the nucleus were enclosed by invaginations of the nuclear envelope. This deformation of the nuclear envelope was confirmed by transmission electron microscopy (TEM) and immuno-TEM. These two techniques also revealed that the HBc aggregates were accumulations of capsid-like shells with an electron-dense material consisting of HBV core fragments. These findings, shedding light on the ultrastructural organization of HBc aggregates, provide insight into the mechanisms of action of BAY 41-4109 against HBV and will serve as a basis for comparison with other HBV capsid assembly inhibitors.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Aggregation; CAMs; Confocal microscopy; Electron microscopy; HBV; HBc

Mesh:

Substances:

Year:  2019        PMID: 31302151     DOI: 10.1016/j.antiviral.2019.104557

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  5 in total

Review 1.  Novel therapeutic strategies for chronic hepatitis B.

Authors:  Sandra Phillips; Ravi Jagatia; Shilpa Chokshi
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

2.  Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses In Vitro and in Humanized Mice.

Authors:  Franck Amblard; Sebastien Boucle; Leda Bassit; Bryan Cox; Ozkan Sari; Sijia Tao; Zhe Chen; Tugba Ozturk; Kiran Verma; Olivia Russell; Virgile Rat; Hugues de Rocquigny; Oriane Fiquet; Maud Boussand; James Di Santo; Helene Strick-Marchand; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

3.  Bay41-4109-induced aberrant polymers of hepatitis b capsid proteins are removed via STUB1-promoted p62-mediated macroautophagy.

Authors:  Jiacheng Lin; Limin Yin; Xia-Zhen Xu; He-Chen Sun; Zhi-Hua Huang; Xue-Yun Ni; Yan Chen; Xu Lin
Journal:  PLoS Pathog       Date:  2022-01-14       Impact factor: 6.823

4.  Design and Synthesis of Hepatitis B Virus (HBV) Capsid Assembly Modulators and Evaluation of Their Activity in Mammalian Cell Model.

Authors:  Karina Spunde; Brigita Vigante; Unda Nelda Dubova; Anda Sipola; Irena Timofejeva; Anna Zajakina; Juris Jansons; Aiva Plotniece; Karlis Pajuste; Arkadij Sobolev; Ruslan Muhamadejev; Kristaps Jaudzems; Gunars Duburs; Tatjana Kozlovska
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-22

Review 5.  Current Progress in the Development of Hepatitis B Virus Capsid Assembly Modulators: Chemical Structure, Mode-of-Action and Efficacy.

Authors:  Hyejin Kim; Chunkyu Ko; Joo-Youn Lee; Meehyein Kim
Journal:  Molecules       Date:  2021-12-07       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.